Skip to main content

Table 5 Summary statistics on consideration of economic items

From: How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?

Item

Considered relevant No. (% of reports)

Severe disease

35 (76%)

Value to caregivers

14 (30%)

Insurance value

0 (0%)

Scientific spillovers

4 (9%)

Lack of alternatives

28 (61%)

Substantial improvement in life expectancy

29 (63%)

Discounting

23 (50%)

Different discount rates employed

18 (39%)

Uncertainty

40 (87%)

Alternative payment models explored

21 (46%)